Human papillomavirus DNA and pap tests: The need for cotesting in opportunistic setting during the transition time

Journal of Lower Genital Tract Disease

Volumn 17, Issue 3, 2013, Pages 362-365

  Mariani, Luciano ^a   Sideri, Mario ^b   Costa, Silvano ^c   Cristoforoni, Paolo ^d   Origoni, Massimo ^e   Preti, Mario ^f  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER PREVENTION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LETTER; META ANALYSIS (TOPIC); PAPANICOLAOU TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGED; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84880345464     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e31826f24c0     Document Type: Letter

References (13)

1. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, RatnamS, et al.Overview of the European andNorth American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101.
2. BulkmansNW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72.
3. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005;93:862-7.
4. Naucler P, Ryd W, Tö rnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357: 1589-97.
5. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-57.
6. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al.Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;377:a1754.
7. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
8. Health Council of the Netherlands. Population screening for cervical cancer. The Hague: Health Council of the Netherlands, 2011 http://www. gezondheidsraad.nl/sites/default/files/201107E%20PopulationSCC-0.pdf.Accessed July 12, 2012.
9. Massad LS. New guidelines on cervical cancer screening: more than just the end of annual pap testing. J Lower Gen Tract Dis 2012;16:172-4.
10. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. J Lower Gen Tract Dis 2012;16:175-204.
11. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12:880-90.
12. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
13. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11: 1048-56.